A father’s crusade in rare disease drug development: a case study of Elpida therapeutics and Melpida
Abstract Therapeutic development for rare diseases is difficult for pharmaceutical companies due to significant scientific challenges, extensive costs, and low financial returns. It is increasingly common for caregivers and patient advocacy groups to partner with biomedical professionals to finance...
| Published in: | Orphanet Journal of Rare Diseases |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Online Access: | https://doi.org/10.1186/s13023-025-03892-0 |